Odonate Therapeutics, Inc.
ODTC · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -176.03 | -0.02 | 0.04 | 2.99 |
| FCF Yield | 0.01% | 1.18% | -50.20% | -6.00% |
| EV / EBITDA | 13,616.35 | 14.50 | -1.29 | -13.87 |
| Quality | ||||
| ROIC | -0.57% | -16.85% | -73.24% | -90.08% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.19 | 0.04 | 1.11 | 0.90 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 386.91% | 102.37% | 33.30% | -17.31% |
| Safety | ||||
| Net Debt / EBITDA | -3.94 | -0.80 | 0.95 | 1.21 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -34.76 | -25.61 | -102.10 | -5,944.05 |